PuSH - Publication Server of Helmholtz Zentrum München

Minimum information about T regulatory cells: A step toward reproducibility and standardization.

Front. Immunol. 8:1844 (2018)
Publishers Version DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
as soon as is submitted to ZB.
Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Minimum Information Model ; T Regulatory Cells ; Immunotherapy ; Good Manufacturing Practice ; Cell Therapy ; Immune Tolerance; Chimeric Antigen Receptor; Versus-host-disease; Adoptive Transfer; In-vitro; Transplantation; Blood; Expansion; Allograft; Tolerance; Therapies
Reviewing status
Institute(s) Institute for Pancreatic Beta Cell Research (IPI)